Phenylketonuria and Duchenne muscular dystrophy: A case report.

K. Roth,R. Cohn,P. Berman,S. Segal

DOI: https://doi.org/10.1016/S0022-3476(76)80038-8

IF: 2.99

1976-04-01

Jornal de Pediatria

Abstract:

What problem does this paper attempt to address?

The Behavioral and Emotional Problems of Patients with Phenylketonuria Early Treated with Dietotherapy

WU Wei,ZHAO Wen-yan,ZHAO Zheng-yan

DOI: https://doi.org/10.3969/j.issn.1673-5293.2006.05.031

2006-01-01

Abstract:Early treated patients with phenylketonuria still have behavioral and emotional problems,including cognitive dysfunction,deficits in executive functioning,attention and introverted behavioral problems and so on.Both the brain damage presenting with pathologic changes in white matter of brain caused by the high phenylalanine concentration and special social environmental factors,including stress from parents concern and diet limit itself,may be responsible for these problems.Many scientists suggest that the dietotherapy should last as long as possible,even till the whole life of the patient,but it is hard to do so.Thus,there have been some researches to explore new alternative approaches for PKU therapy,including gene therapy,enzyme replacement therapy and large doses of neutral amino acids therapy.
Pitfalls in the Management of Phenylketonuria in China

L. L. Yang,H. Q. Mao,W. F. Zhang,Z. Y. Zhao,R. L. Yang,X. L. Zhou,X. L. Huang,X. W. Huang

2012-01-01

Hong kong journal of paediatrics

Abstract:To review the cognitive outcome of phenylketonuria (PKU) patients who were diagnosed through the newborn screening program. The management and treatment procedures were also evaluated. All PKU files during the period from January 1999 to September 2010 were reviewed and evaluated. The demographic information of the patients, results of average phenylalanine (Pile) concentration in the first three years, Phe concentration at the most recent clinic visit and neuropsychological assessment were recorded in detail. A total of 3,791,538 newborns had been screened for PKU in our centre. PKU was diagnosed in 147 children after newborn screening with an incidence of 1/25,600. After diagnosis, 24 children were refused to be treated by their parents. Four children were discontinued treatment after a period by their parents and nine were lost during the follow-up. Only 96 children have been followed up and treated at our centre until now. Neuropsychological assessments were only done in 55 patients, 11 of whom had mental retardation. The outcome of the children with delayed diagnosis and treatment was poor. Non-compliance to the treatment was common in PKU patients. Urgent measures have to be done to improve the screening strategies. Future study should focus on investigating the possible factors resulting in poor or suboptimal compliance, so as to improve the outcome of the PKU children.
The role of membrane transporters in drug delivery to brain tumors.

A. Nies

DOI: https://doi.org/10.1016/J.CANLET.2006.12.023

IF: 9.756

2007-08-28

Cancer Letters

Abstract:
Kinetic evidence for the formation of oxazolidinones in the stereogenic step of proline-catalyzed reactions.

Tanja Kanzian,S. Lakhdar,H. Mayr

DOI: https://doi.org/10.1002/anie.201004344

2010-12-03

Angewandte Chemie

Abstract:
Mental and motor development and psychosocial adjustment of Chinese children with phenylketonuria.

Wei Wu,Diying Sheng,Jie Shao,Zhengyan Zhao

DOI: https://doi.org/10.1111/j.1440-1754.2010.01996.x

2011-01-01

Journal of Paediatrics and Child Health

Abstract:Aim: This study was designed to evaluate mental and motor development, psychosocial adjustment (temperament and behavioural problems) in children with phenylketonuria (PKU). Methods: Twenty-eight Chinese children aged from three to 36 months with early-treated PKU were evaluated by Bayley Scales of Infant Development (BSID), Peabody Developmental Motor Scale (PDMS-II), Toddler Temperament Questionnaire (TTQ) and Achenbach's Child Behavior Checklist (CBCL). The related factors, including blood phenylalanine (Phe) levels, and the socio-economic status (SES) of the children's family were also explored. Results: In comparison with healthy control, early-treated PKU children showed no delay in the mental and motor development. However, they presented higher levels on four of the nine temperamental dimensions (higher level in activity, more intense in reaction, more negative mood and more distraction). They also had more behavioural problems in depression, aggression and destructibility. A lower Phe level and a higher SES of children's family showed a positive effect on development index, temperamental characteristics and behavioural problems. Conclusion: Early-treated PKU children were normal in the mental and motor development. However, they presented higher level on four of the nine temperamental dimensions and had more behavioural problems. Paediatric control combined with psycho-counselling was suggested for young PKU children.
Malignant Phenylketonuria Presented with Paroxysmal Movement Disorders: Report of One Case and Review of the Literature

刘爱琳,张宏文,熊晖,顾强

DOI: https://doi.org/10.3969/j.issn.1674-3865.2009.06.001

2009-01-01

Abstract:Objective Phenylketonuria(PKU) is an autosomal recessive inborn error of phenylalanine(Phe) metabolism resulting from deficiency of phenylalanine hydroxylase(PAH).Fewer phenylketonuria results from deficiency of tetrahydrobiopterin(BH4),called malignant phenylketonuria,which was often misdiagnosed for its variant phenotype.Method A malignant phenylketonuria patient presented with paroxysmal movement disorders was studied via blood phenylalanine measurement,urine metabolism screening,phenylalanine and tetrahydrobiopterin stress test,and urine petrin analysis.A comprehensive analysis was made based on literature.Result A little one-year-and-six-month old girl presented with paroxysmal movement disorders;her blood phenylalanine concentration was normal;urine metabolism screening suggested phenylketonuria.She was diagnosed with malignant phenylketonuria according to phenylalanine and tetrahydrobiopterin stress test and urine petrin analysis.Conclusion There is a high incidence and misdiagnosis rate for malignant phenylketonuria in China,so more attention should be paid to it in clinic.
Perspectives and Insights Into Phenylketonuria: Provider Narratives About the Early Years Following Newborn Screening

Suzanne Hollander,Harvey Levy,Fran Rohr,Susan Waisbren,Priscila Rincon,Ann Wessel,Stephanie Sacharow

DOI: https://doi.org/10.1002/ajmg.c.32111

Abstract:The understanding of phenylketonuria (PKU), guidelines, and treatment landscape have evolved dramatically over the decades since newborn screen implementation. We capture this rich history from the stories and experiences of a multidisciplinary provider team from Boston Children's Hospital's PKU Clinic, who treated PKU from the early years of newborn screening and who worked together for over 40 years.
Emphasis on the importance of comprehensive clinical and genetic analysis - spinal muscular atrophy combined with phenylketonuria: A case report

Kai Ma,Dong Wang,Wandong Hu,Jie Wang,Chunmei Yu,Zhenqiong Cui,Fangfang Liu

DOI: https://doi.org/10.1097/MD.0000000000039076

2024-08-02

Abstract:Rationale: Both spinal muscular atrophy (SMA) and Phenylketonuria (PKU) are caused by biallelic pathogenic mutations. However, there has been no report on case who suffering from both diseases simultaneously. SMA mainly affects the motor function while PKU may have an impact on both the intelligence and motor function. But if only 1 disease is treated while neglecting the other, the treatment effect will be compromised. Here, for the first time, we report a case from China diagnosed with both these diseases and treated properly. Patient concerns: A boy was admitted to the Children's Hospital Affiliated to Shandong University (Jinan, China) due to "limb weakness for 19 months" when he was 22 months old. Considering that the child's motor function development is delayed, we made a comprehensive examinations including inherited metabolic diseases and found a significantly increase of phenylalanine concentration in the blood which indicating PKU. Combined with his typical clinical manifestations of SMA, target capture sequencing followed by Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) technologies were used for genetic confirmation. Diagnoses: SMA and PKU was confirmed. Interventions: The child was treated with risdiplam and low phenylalanine formula immediately when he was diagnosed with both SMA and PKU. Outcomes: The child showed remarkable improvement in motor function and significant decrease of blood phenylalanine concentration after treatment. Lessons: To our knowledge, this is the first reported case of SMA combined with PKU. This case expands our understanding of diagnosis for synchronous SMA and PKU and highlights the importance of comprehensive examinations and the utilizing of various genetic testing methods to make an accurate diagnosis of genetic diseases, which may help avoiding the progressive damage caused by certain genetic disease with insidious clinical symptoms.
Preparing Enteral Formulas for Adult Patients with Phenylketonuria: A Minor Necessity but Major Challenge—A Case Report

Adriana Pané,Marcos Carrasco-Serrano,Camila Milad,Pere Leyes,Pedro Juan Moreno-Lozano,Roser Ventura,José Cesar Milisenda,Francesc Josep García-García,Glòria Garrabou,Judit García-Villoria,Rosa Maria López-Galera,Antonia Ribes,Josep Maria Grau-Junyent,Maria de Talló Forga-Visa,Cristina Montserrat-Carbonell,

DOI: https://doi.org/10.3390/jcm12237452

IF: 3.9

2023-12-01

Journal of Clinical Medicine

Abstract:Phenylketonuria (PKU) is the most frequent of the congenital errors of amino acid (AA) metabolism worldwide. It leads to the accumulation of the essential AA phenylalanine (Phe) and it is associated with severe neurological defects. The early diagnosis and treatment of this rare disease, achieved through newborn screening and low-Phe diet, has profoundly changed its clinical spectrum, resulting in normal cognitive development. We face the first generation of PKU patients perinatally diagnosed and treated who have reached adulthood, whose special needs must be addressed, including feeding through enteral nutrition (EN). However, recommendations regarding EN in PKU constitute a gap in the literature. Although protein substitutes for patients with PKU are offered in multiple forms (Phe-free L-amino acid or casein glycomacropeptide supplements), none of these commercial formulas ensures the whole provision of daily total energy and protein requirements, including a safe amount of Phe. Consequently, the combination of different products becomes necessary when artificial nutrition via tube feeding is required. Importantly, the composition of these specific formulas may result in physicochemical interactions when they are mixed with standard EN products, leading to enteral feeding tubes clogging, and also gastrointestinal concerns due to hyperosmolality. Herein, we present the first reported case of EN use in an adult patient with PKU, where the separate administration of protein substitutes and the other EN products avoided physicochemical interactions.

medicine, general & internal
Navigating social determinants of health barriers in the management of phenylketonuria

Ashley Andrews,Kate McMinimee

DOI: https://doi.org/10.1016/j.ymgmr.2024.101080

2024-05-03

Abstract:Phenylketonuria (PKU) is an inborn error of amino acid metabolism that is typically identified by newborn screening. With lifelong treatment consisting of dietary management, frequent laboratory monitoring, and regular metabolic clinic visits, patients with PKU can maintain good health and metabolic control. Here, we describe the case of an 8-year-old patient with PKU who has been followed by a metabolic clinic since birth. Despite responsiveness to sapropterin, this patient has had periods of poor metabolic control throughout her life due to her family's economic hardships, including limited access to transportation, housing, food, and health insurance. This case illustrates how social determinants of health may negatively affect rare disease management and potential strategies for addressing barriers to care.
Phenylketonuria - newborn screening as a health protection in society

Katarzyna Piotrowicz,Hubert Piotrowicz,Jacek Kurzeja,Emilia Żurowska

DOI: https://doi.org/10.36740/WLek202408111

Abstract:Objective: Aim: Phenylketonuria is the most prevalent inherited metabolic disorder. Early detection and prompt treatment can prevent serious neurological consequences. This has become possible thanks to the implementation of newborn screening programmes. The objective of this review is to provide readers with a comprehensive understanding of the phenylketonuria and the role that neonatal screening plays in the protection of public health. Patients and methods: Materials and Methods: A review of the literature was conducted using the PubMed database, with the search period encompassing the most recently published scientific sources. Analysis of the literature. This article presents phenylketonuria as an example of an inherited metabolic disorder, outlines the treatment options, and discusses the potential implications of hyperphenylalaninemia. Furthermore, it also delineates the various aspects of health that are influenced by newborn screening. Conclusion: Conclusions: Phenylketonuria represents a significant health problem in the population. The development of screening tests has transformed healthcare, including improvements in quality of life, prognosis, and reductions in the number of comorbidities in patients. It is essential to disseminate knowledge among the society about the importance of newborn screening tests in order to enhance awareness and prevent refusal to participate.
Multiplex detection of Ehrlichia and Anaplasma species pathogens in peripheral blood by real-time reverse transcriptase-polymerase chain reaction.

Kamesh R. Sirigireddy,R. Ganta

DOI: https://doi.org/10.1016/S1525-1578(10)60559-4

IF: 5.341

2005-05-01

Journal of Molecular Diagnostics

Abstract:
Emerging biosensors in Phenylketonuria

Ritika Shyam,Himanshu Sekhar Panda,Jibanananda Mishra,Jiban Jyoti Panda,Avneet Kour

DOI: https://doi.org/10.1016/j.cca.2024.119725

IF: 6.314

2024-05-11

Clinica Chimica Acta

Abstract:Phenylketonuria (PKU) is an autosomal recessive metabolic disorder resulting from deficient phenylalanine hydroxylase (PAH) enzyme activity, leading to impaired phenylalanine (Phe) metabolism. This condition can lead to intellectual disability, epilepsy, and behavioural issues. Treatment typically involves strict dietary restrictions on natural protein intake, supplemented with chemically manufactured protein substitutes containing amino acids other than Phe. Various approaches, including casein glycomacropeptide (GMP), tetrahydrobiopterin (BH 4 ), phenylalanine ammonia-lyase (PAL) therapy, large neutral amino acid (LNAA) supplementation, enzyme therapy, gene therapy, and medical therapies, aim to prevent Phe transport in the brain and potentially treat PKU. Although newborn screening programs and early dietary interventions have enhanced outcomes of the potential treatment strategies, limitations still persist in this direction. These involve potent accuracy concerns in diagnosis due to the existence of antibiotics in blood of PKU patients, affecting growth of the bacteria in the bacterial inhibition assay. Monitoring involves complex methods for instance, mass spectrometry and high-pressure liquid chromatography, which involve shortcomings such as lengthy protocols and the need for specialized equipment. To address these limitations, adaptable testing formats like bio/nano sensors are emerging with their cost-effectiveness, biodegradability, and rapid, accurate, and sensitive detection capabilities, offering promising alternatives for PKU diagnosis. This review provides insights into current treatment and diagnostic approaches, emphasizing on the potential applications of the diverse sensors intended for PKU diagnosis.

medical laboratory technology
Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria

Mehmet Cihan Balci,Meryem Karaca,Dilek Gunes,Huseyin Kutay Korbeyli,Arzu Selamioglu,Gulden Gokcay

DOI: https://doi.org/10.3390/nu16193355

IF: 5.9

2024-10-03

Nutrients

Abstract:Background/Objectives: Phenylketonuria is a hereditary metabolic disorder characterized by a deficiency of phenylalanine hydroxylase. The main treatment for PKU is a phenylalanine-restricted diet. The exclusion of protein rich natural foods and inclusion of low-Phe substitutes may give rise to an imbalanced diet, and the increased risk of overweight and obesity in PKU is a cause for concern. We aimed to evaluate the body composition and nutritional biochemical biomarkers in adult PKU patients who are on Phe-restricted and essential amino acid-supplemented nutrition therapy and to investigate the relationships between these parameters and patient gender, adherence to dietary therapy, and disease type, defined as mild or classic PKU. Methods: The study group comprised 37 PKU patients and 26 healthy siblings as controls. The participants were assessed based on an analysis of anthropometric parameters, body composition, and biochemical test results. Results: PKU patients do not have a higher incidence of overweight and obesity than healthy controls, the proportion of energy derived from carbohydrates in their diets was below the recommended level, and their total energy intake was below the recommended daily allowance. It was remarkable that patients with a treatment adherence ratio of <50% displayed a higher prevalence of overweight and abdominal obesity in comparison to those with a more favorable treatment adherence ratio. Conclusions: In view of the growing prevalence of overweight in the general population, PKU patients should be kept under close long-term follow-up. Particularly in the group with low treatment compliance, more caution should be taken in terms of adverse outcomes.

nutrition & dietetics
Molecular diagnosis of Phenylketonuria in 157 Families and Prenatal Diagnosis of Phenylketonuria

Yang Xiao,Qiang Gu,Hairong Wu,Songtao Wang,Pei Pei,Xuefei Zheng,Hong Pan,Yinan MA

DOI: https://doi.org/10.21203/rs.2.16584/v1

2019-01-01

Abstract:Abstract Background Phenylketonuria (PKU) is a genetic metabolic disease with a relatively higher incidence, but only a few studies about the prenatal diagnosis of PKU have been reported so far in China. The aim of this study was to characterize the spectrum of mutations in PAH gene in PKU probands and the prenatal diagnosis of PKU in north China.Methods A total of 157 families in which PKU patients had been diagnosed were included in the study. The 13 exons and their flanking sequences of PAH gene were amplified by PCR and sequenced in the probands. If none or only one mutant allele was found in the probands, the sample was subjected to MLPA for large deletions/duplication detection in PAH gene. Prenatal diagnosis was performed for pregnant women in these families.Results Pathogenic mutation in PAH was found in 2 alleles in 148 probands and in one allele in 7 probands, and the mutation was not detected in 2 probands. There were 289 point mutants, 10 frame-shift mutations and 4 large deletions with a total of 80 kinds of mutations. The most prevalent mutations were R243Q (17.2%), EX6-96A>G (8.6%) and V399V (8.0%). We also found a novel mutation of 163_164insATAT. Prenatal diagnosis of 95 families found 21 healthy fetus (20.4%), 52 carriers (50.5%) and 30 patients (29.1%), and the accuracy of prenatal diagnosis was confirmed after birth of the fetuses.Conclusion We present here a spectrum of mutations in PAH gene in PKU patients in north China. Prenatal diagnosis for PKU is useful for PKU families to prevent birth of another PKU case.
An adaptable and reliable authentication protocol for communication networks

Taekyoung Kwon,Myeongho Kang,Joo-Seok Song

DOI: https://doi.org/10.1109/INFCOM.1997.644527

1997-04-09

Abstract:We propose a new authentication and key distribution protocol which is adaptable and reliable for communication networks. The secrets for authentication, which are chosen from a relatively small space by common users, are easy to guess. Our protocol gives a solution to protect the weak secrets from guessing attacks. Compared with other related work, our protocol is more reliable because it is resistant to various kinds of attacks including guessing attacks, and more adaptable because it reduces several overheads which make the existing protocols more expensive. We show how to apply our protocol to the Q.931 calling sequences and to the World Wide Web model.
Phenylketonuria oxidative stress and energy dysregulation: Emerging pathophysiological elements provide interventional opportunity

Steven F Dobrowolski,Yu Leng Phua,Jerry Vockley,Eric Goetzman,Harry C Blair

DOI: https://doi.org/10.1016/j.ymgme.2022.03.012

Abstract:Phenylalanine hydroxylase (PAH) deficient phenylketonuria (PKU) is rightfully considered the paradigm treatable metabolic disease. Dietary substrate restriction (i.e. phenylalanine (Phe) restriction) was applied >60 years ago and remains the primary PKU management means. The traditional model of PKU neuropathophysiology dictates blood Phe over-representation directs asymmetric blood:brain barrier amino acid transport through the LAT1 transporter with subsequent increased cerebral Phe concentration and low concentrations of tyrosine (Tyr), tryptophan (Trp), leucine (Leu), valine (Val), and isoleucine (Ile). Low Tyr and Trp concentrations generate secondary serotonergic and dopaminergic neurotransmitter paucities, widely attributed as drivers of PKU neurologic phenotypes. White matter disease, a central PKU characteristic, is ascribed to Phe-mediated tissue toxicity. Impaired cerebral protein synthesis, by reduced concentrations of non-Phe large neutral amino acids, is another cited pathological mechanism. The PKU amino acid transport model suggests Phe management should be more efficacious than is realized, as even early identified, continuously treated patients that retain therapy compliance into adulthood, demonstrate neurologic disease elements. Reduced cerebral metabolism was an early-recognized element of PKU pathology. Legacy data (late 1960's to mid-1970's) determined the Phe catabolite phenylpyruvate inhibits mitochondrial pyruvate transport. Respirometry of Pahenu2 cerebral mitochondria have attenuated respiratory chain complex 1 induction in response to pyruvate substrate, indicating reduced energy metabolism. Oxidative stress is intrinsic to PKU and Pahenu2 brain tissue presents increased reactive oxygen species. Phenylpyruvate inhibits glucose-6-phosphate dehydrogenase that generates reduced niacinamide adenine dinucleotide phosphate the obligatory cofactor of glutathione reductase. Pahenu2 brain tissue metabolomics identified increased oxidized glutathione and glutathione disulfide. Over-represented glutathione disulfide argues for reduced glutathione reductase activity secondary to reduced NADPH. Herein, we review evidence of energy and oxidative stress involvement in PKU pathology. Data suggests energy deficit and oxidative stress are features of PKU pathophysiology, providing intervention-amenable therapeutic targets to ameliorate disease elements refractory to standard of care.
Analysis of Phenylketonuria in 39 Children

LIU Yan,HAN Ying,GU Qiang,YANG Yan-ling,QIN Jiong

2010-01-01

Abstract:Objective To investigate the clinical diagnosis,therapy and prognosis of children with phenylketonuria(PKU),and to analyze the possible causes of misdiagnosis.Methods The detailed data of 39 cases with PKU[male 21 cases,femal 18 cases;nosopoietic age was(8.79±11.28) months;diagnostic age was (2.48±2.72) years] admitted from Jan.1993 to Oct.2008 were analyzed retrospectively,including clinical manifestation,final diagnosis,misdiagnosis analysis,perspective therapy.Results The clinical manifestations of PKU in this group included mental retardation in all 39 cases,epilepsy in 26 cases,abnormal rat-like odor in 21 cases,language delay in 11 cases and dyskinesia in 2 cases.The electroencephalogram was abnormal in 29 cases.The magnetic resonance imaging showed abnormalities in 5 cases.All children had been regarded as mental retardation or congenital developmental problems,the courses of the disease before final diagnosis were(1.75±2.55) years,15 cases of them had been misdiagnosed as cerebral palsy or atelencephalia.Three cases manifested as movement disorders or epileptic seizures,hypopigmentation or rat-like odor.They were identified as tetrahydrobiopterin deficiency through urine pterin analysis and tetrahydrobiopterin tolerance test.Conclusions The clinical manifestations of PKU mainly include mental retardation,developmental delay,epileptic seizures,and movement disorders.Early diagnosis and prompt intervention are the key for a satisfactory long-term prognosis.It is not easy,however,to make a correct diagnosis for children with PKU missing the neonatal routine screening test.Tetrahydrobiopterin tolerance test is of value for the identification of atypical PKU.
Phenylketonuria (PKU) Urinary Metabolomic Phenotype Is Defined by Genotype and Metabolite Imbalance: Results in 51 Early Treated Patients Using Ex Vivo 1H-NMR Analysis

Claire Cannet,Allan Bayat,Georg Frauendienst-Egger,Peter Freisinger,Manfred Spraul,Nastassja Himmelreich,Musa Kockaya,Kirsten Ahring,Markus Godejohann,Anita MacDonald,Friedrich Trefz

DOI: https://doi.org/10.3390/molecules28134916

IF: 4.6

2023-06-22

Molecules

Abstract:Phenylketonuria (PKU) is a rare metabolic disorder caused by mutations in the phenylalanine hydroxylase gene. Depending on the severity of the genetic mutation, medical treatment, and patient dietary management, elevated phenylalanine (Phe) may occur in blood and brain tissues. Research has recently shown that high Phe not only impacts the central nervous system, but also other organ systems (e.g., heart and microbiome). This study used ex vivo proton nuclear magnetic resonance (1H-NMR) analysis of urine samples from PKU patients (mean 14.9 ± 9.2 years, n = 51) to identify the impact of elevated blood Phe and PKU treatment on metabolic profiles. Our results found that 24 out of 98 urinary metabolites showed a significant difference (p < 0.05) for PKU patients compared to age-matched healthy controls (n = 51) based on an analysis of urinary metabolome. These altered urinary metabolites were related to Phe metabolism, dysbiosis, creatine synthesis or intake, the tricarboxylic acid (TCA) cycle, end products of nicotinamide-adenine dinucleotide degradation, and metabolites associated with a low Phe diet. There was an excellent correlation between the metabolome and genotype of PKU patients and healthy controls of 96.7% in a confusion matrix model. Metabolomic investigations may contribute to a better understanding of PKU pathophysiology.
Effect of enzyme substitution therapy on brain magnetic resonance imaging and cognition in adults with phenylketonuria: A case series of three patients

Alessandro P. Burlina,Renzo Manara,Jessica Carretta,Chiara Cazzorla,Christian Loro,Vincenza Gragnaniello,Alberto B. Burlina

DOI: https://doi.org/10.1111/ene.16508

2024-10-05

European Journal of Neurology

Abstract:Phenylketonuria, the most common inherited metabolic disease, results from a deficiency of phenylalanine hydroxylase enzyme activity that causes high blood phenylalanine levels. Most adults do not adhere to the gold standard therapy: lifelong treatment with a low‐phenylalanine diet. Elevated and fluctuating phenylalanine levels in untreated adults can cause white matter abnormalities, neurological symptoms, and cognitive dysfunction (executive function). Pegvaliase, a derivative of the phenylalanine ammonia‐lyase enzyme, metabolizes phenylalanine to trans‐cinnamic acid and ammonia, and is approved by the US Food and Drug Administration and European Medicines Agency for subcutaneous administration in adults with phenylketonuria and blood phenylalanine concentrations > 600 μmol/L. In clinical trials, it reduced blood phenylalanine, even in patients consuming an unrestricted diet. We report longitudinal results on the first three such adults, in whom phenylalanine levels were quantified monthly, starting 1 year before pegvaliase administration and continuing through achievement of a pegvaliase response (defined as six consecutive monthly blood phenylalanine concentrations

neurosciences,clinical neurology

Phenylketonuria and Duchenne muscular dystrophy: A case report.

The Behavioral and Emotional Problems of Patients with Phenylketonuria Early Treated with Dietotherapy

Pitfalls in the Management of Phenylketonuria in China

The role of membrane transporters in drug delivery to brain tumors.

Kinetic evidence for the formation of oxazolidinones in the stereogenic step of proline-catalyzed reactions.

Mental and motor development and psychosocial adjustment of Chinese children with phenylketonuria.

Malignant Phenylketonuria Presented with Paroxysmal Movement Disorders: Report of One Case and Review of the Literature

Perspectives and Insights Into Phenylketonuria: Provider Narratives About the Early Years Following Newborn Screening

Emphasis on the importance of comprehensive clinical and genetic analysis - spinal muscular atrophy combined with phenylketonuria: A case report

Preparing Enteral Formulas for Adult Patients with Phenylketonuria: A Minor Necessity but Major Challenge—A Case Report

Navigating social determinants of health barriers in the management of phenylketonuria

Phenylketonuria - newborn screening as a health protection in society

Multiplex detection of Ehrlichia and Anaplasma species pathogens in peripheral blood by real-time reverse transcriptase-polymerase chain reaction.

Emerging biosensors in Phenylketonuria

Evaluation of Body Composition and Biochemical Parameters in Adult Phenylketonuria

Molecular diagnosis of Phenylketonuria in 157 Families and Prenatal Diagnosis of Phenylketonuria

An adaptable and reliable authentication protocol for communication networks

Phenylketonuria oxidative stress and energy dysregulation: Emerging pathophysiological elements provide interventional opportunity

Analysis of Phenylketonuria in 39 Children

Phenylketonuria (PKU) Urinary Metabolomic Phenotype Is Defined by Genotype and Metabolite Imbalance: Results in 51 Early Treated Patients Using Ex Vivo 1H-NMR Analysis

Effect of enzyme substitution therapy on brain magnetic resonance imaging and cognition in adults with phenylketonuria: A case series of three patients